Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis

Kensuke Shoji; Yusuke Asai; Takayuki Akiyama; Shinya Tsuzuki; Nobuaki Matsunaga; Setsuko Suzuki; Noriko Iwamoto; Takanori Funaki; Isao Miyairi; Norio Ohmagari

doi:10.1016/j.jiac.2023.06.006

Clinical efficacy of remdesivir for COVID-19 in children: A propensity-score-matched analysis

J Infect Chemother. 2023 Sep;29(9):930-933. doi: 10.1016/j.jiac.2023.06.006. Epub 2023 Jun 12.

Authors

Affiliations

¹ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan. Electronic address: shoji-k@ncchd.go.jp.
² AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
³ AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
⁴ AMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan; Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan; Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
⁵ Department of Infectious Diseases, Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
⁶ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan.
⁷ Division of Infectious Diseases, Department of Medical Subspecialties, National Center for Child Health and Development, Tokyo, Japan; Department of Pediatrics, Hamamatsu University School of Medicine, Hamamatsu, Shizuoka, Japan.

Abstract

Clinical efficacy of remdesivir in children with COVID-19 is unclear. This propensity-score-matched retrospective cohort study of children with COVID-19 showed that the rate of patients achieving defervescence on Day 4 was higher in the remdesivir group than in the non-remdesivir group, but was not statistically different (86.7% vs 73.3%, P = 0.333).

Keywords: Children; Coronavirus disease 2019; Defervescence; Remdesivir; Severe acute respiratory syndrome coronavirus 2.

Copyright © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

MeSH terms

Alanine / therapeutic use
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment
COVID-19*
Child
Humans
Retrospective Studies
SARS-CoV-2
Treatment Outcome

Substances

Antiviral Agents
Alanine